[go: up one dir, main page]

DE60316189D1 - P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon - Google Patents

P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon

Info

Publication number
DE60316189D1
DE60316189D1 DE60316189T DE60316189T DE60316189D1 DE 60316189 D1 DE60316189 D1 DE 60316189D1 DE 60316189 T DE60316189 T DE 60316189T DE 60316189 T DE60316189 T DE 60316189T DE 60316189 D1 DE60316189 D1 DE 60316189D1
Authority
DE
Germany
Prior art keywords
honichiosis
antigenes
immunization
dogs
humans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60316189T
Other languages
English (en)
Other versions
DE60316189T2 (de
Inventor
Jere W Mcbride
David H Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Application granted granted Critical
Publication of DE60316189D1 publication Critical patent/DE60316189D1/de
Publication of DE60316189T2 publication Critical patent/DE60316189T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60316189T 2002-11-04 2003-11-04 P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon Expired - Fee Related DE60316189T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42357302P 2002-11-04 2002-11-04
US423573P 2002-11-04
PCT/US2003/034916 WO2004042037A1 (en) 2002-11-04 2003-11-04 P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof

Publications (2)

Publication Number Publication Date
DE60316189D1 true DE60316189D1 (de) 2007-10-18
DE60316189T2 DE60316189T2 (de) 2007-12-20

Family

ID=32312680

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60316189T Expired - Fee Related DE60316189T2 (de) 2002-11-04 2003-11-04 P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon

Country Status (13)

Country Link
US (2) US7204992B2 (de)
EP (1) EP1581638B1 (de)
JP (1) JP4494974B2 (de)
KR (1) KR101063177B1 (de)
CN (2) CN100386430C (de)
AT (1) ATE372378T1 (de)
AU (1) AU2003290575B2 (de)
BR (1) BRPI0315980B1 (de)
CA (1) CA2504762A1 (de)
DE (1) DE60316189T2 (de)
ES (1) ES2293057T3 (de)
MX (1) MXPA05004804A (de)
WO (1) WO2004042037A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842473B2 (en) 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
US7842474B2 (en) 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
MX2007016189A (es) 2005-06-16 2008-03-10 Res Dev Foundation Ortologos de proteinas inmunoreactivas de ehrlichia canis y e. chaffeensis.
EP2187958B1 (de) 2007-09-11 2016-12-21 Yissum Research Development Company of the Hebrew University of Jerusalem Abgeschwächter ehrlichiose-impfstoff
WO2009039414A2 (en) 2007-09-21 2009-03-26 Idexx Laboratories, Inc. Methods and compositions for detection of ehrlichia chaffeensis (vlpt)
EP2045816A1 (de) * 2007-10-01 2009-04-08 Paul Scherrer Institut Schnelles Auslesungsverfahren und Schaltkondensator-Arrayschaltung zur Wellenform-Digitalisierung
MX2010004735A (es) * 2007-10-31 2010-05-20 Idexx Lab Inc Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis.
JP5677703B2 (ja) 2008-01-10 2015-02-25 リサーチ ディベロップメント ファウンデーション Ｅｈｒｌｉｃｈｉａｃｈａｆｆｅｅｎｓｉｓにのためのワクチンおよび診断
ES2596952T3 (es) 2009-11-20 2017-01-13 Abaxis, Inc. Péptidos, dispositivos y procedimientos para la detección de anticuerpos de Ehrlichia
WO2012003205A2 (en) * 2010-07-02 2012-01-05 Intervet International B.V. Vaccine against ehrlichia canis and associated methods
WO2014059274A1 (en) 2012-10-11 2014-04-17 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
US9194870B2 (en) 2014-01-21 2015-11-24 Abaxis, Inc. Peptides, devices, and methods for the detection of Anaplasma antibodies
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
JP2022540197A (ja) * 2019-07-12 2022-09-14 リサーチ ディベロップメント ファウンデーション エーリキアワクチンおよび免疫原性組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653128B2 (en) 1996-10-17 2003-11-25 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
US6403093B1 (en) * 1997-03-21 2002-06-11 Mayo Foundation For Medical Education And Research Methods to detect granulocytic ehrlichiosis
US6207169B1 (en) * 1997-03-21 2001-03-27 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
US6436399B1 (en) * 1998-04-09 2002-08-20 The Ohio State University Research Foundation Nucleic acid encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
EP1069827A4 (de) * 1998-04-09 2003-06-18 Ohio State Res Found Die äusseren membranproteine des humanen granulcytischen ehrlichiose-agens kodierenden nukleinsäuren
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US6544517B1 (en) * 1998-09-18 2003-04-08 The Ohio State University Research Foundation Outer membrane protein of Ehrlichia canis and Ehrlichia chaffeensis
US6355777B1 (en) * 2000-04-28 2002-03-12 Research Development Foundation P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof
US6512005B2 (en) 2001-02-28 2003-01-28 Taro Pharmaceutical Industries, Ltd. Process for synthesis of pure warfarin acid, warfarin alkali metal salts and corresponding clathrates

Also Published As

Publication number Publication date
CN100386430C (zh) 2008-05-07
US7754224B2 (en) 2010-07-13
MXPA05004804A (es) 2005-12-05
EP1581638A4 (de) 2005-12-28
CA2504762A1 (en) 2004-05-21
BRPI0315980B1 (pt) 2016-03-29
CN1735684A (zh) 2006-02-15
US20070218082A1 (en) 2007-09-20
ES2293057T3 (es) 2008-03-16
JP4494974B2 (ja) 2010-06-30
AU2003290575B2 (en) 2009-10-29
CN101294162A (zh) 2008-10-29
DE60316189T2 (de) 2007-12-20
EP1581638B1 (de) 2007-09-05
AU2003290575A1 (en) 2004-06-07
ATE372378T1 (de) 2007-09-15
US20040121433A1 (en) 2004-06-24
BR0315980A (pt) 2005-09-20
KR101063177B1 (ko) 2011-09-08
WO2004042037A1 (en) 2004-05-21
CN101294162B (zh) 2011-03-30
KR20050084679A (ko) 2005-08-26
US7204992B2 (en) 2007-04-17
JP2006505270A (ja) 2006-02-16
EP1581638A1 (de) 2005-10-05

Similar Documents

Publication Publication Date Title
DE60316189D1 (de) P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
DE60124899D1 (de) Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
DK1090039T3 (da) Peptidsammensætning som immunogen til behandling af allergi
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
WO2004045529A3 (en) West nile virus vaccine
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
DE60130998D1 (de) Ribavirin-enthaltende vakzine
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
ATE453714T1 (de) Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
EP1262491A3 (de) Nicht-anaphylaktogene IgE Impfstoffe
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
CY1105947T1 (el) Νουκλεϊνικα οξεα και πρωτεϊνες του γονιδιου mhp3 του mycoplasma hyopneumoniae και χρησεις αυτων
WO2005056051A3 (en) Hepatitis b vaccines and compositions
ATE433326T1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ATE382365T1 (de) Thymosin-augmentation bei genetischer immunisierung
ATE414154T1 (de) Moraxella (branhamella) catarrhalis antigene

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee